Download PDF
TumorDiagnostik & Therapie 2017; 38(04): 240-242
DOI: 10.1055/s-0043-103164
Thieme Onkologie aktuell
© Georg Thieme Verlag KG Stuttgart · New York

Hochrisikopatientin mit BRCA-1-Mutation – Risikofaktor Restdrüsengewebe nach prophylaktischer Mastektomie

Julia Téoule
,
Aba Harcos
,
Christof Sohn
,
Jörg Heil
,
Sarah Schott
Further Information

Publication History

Publication Date:
09 May 2017 (online)

Also available at
    Permissions and Reprints

Fallvorstellung

Eine 39-jährige Patientin mit einer bekannten BRCA-1-Mutation stellt sich in unserer mammachirurgischen-rekonstruktiven Sprechstunde zur Zweitmeinung vor. Zuvor war eine prophylaktische Mastektomie beidseits (SCM) über eine periareoläre Schnittführung mit Prothesenimplantation sowie anschließendem Lipofilling erfolgt. Vorstellungsgrund nach dem prophylaktischen Eingriff war die Unzufriedenheit der Ratsuchenden mit dem ästhetischen Ergebnis. Sekundär wurde die Frage nach verbliebenem Restdrüsengewebe im Gespräch adressiert.

 

  • Literatur

  • 1 Thompson DJ. et al. Research article Assessing the usefulness of a novel MRI-based breast density estimation algorithm in a cohort of women at high genetic risk of breast cancer : the UK MARIBS study. Breast Cancer Research 2009; 11: 1-16
    PubMedGoogle Scholar
  • 2 Baltzer HL. et al. MRI Volumetric Analysis of Breast Fibroglandular Tissue to Assess Risk of the Spared Nipple in BRCA1 and BRCA2 Mutation Carriers. Ann Surg Oncol 2014; 21: 1583-1588
    CrossrefPubMedGoogle Scholar
  • 3 van Verschuer VMT. Maijers MC. van Deurzen CHM. et al. Oncological safety of prophylactic breast surgery: skin-sparing and nipple-sparing versus total mastectomy. Gland Surg 2015; 4: 467-475
    PubMedGoogle Scholar
  • 4 Manning AT. et al. Nipple-sparing mastectomy in patients with BRCA1/2 mutations and variants of uncertain significance. Br J Surg 2015; 102: 1354-1359
    CrossrefPubMedGoogle Scholar
  • 5 Mavaddat N. et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: Results from prospective analysis of EMBRACE. J Natl Cancer Inst 2013; 105: 812-822
    CrossrefPubMedGoogle Scholar
  • 6 Rhiem K. et al. The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study. Breast Cancer Res 2012; 14: R156
    CrossrefPubMedGoogle Scholar
  • 7 Domchek SM. et al. Europe PMC Funders Group Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers with Cancer Risk and Mortality. JAMA 2010; 304: 967-975
    CrossrefPubMedGoogle Scholar
  • 8 Hartmann LC. Schaid DJ. Woods JE. et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999; 340: 77-84
    CrossrefPubMedGoogle Scholar
  • 9 Rebbeck TR. et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE study group. J Clin Oncol 2004; 22: 1055-1062
    CrossrefPubMedGoogle Scholar
  • 10 Meijers-Heijboer H. van Geel B. van Putten WL. et al. Breast Cancer after Prophylactic Bilateral Mastectomy in Women with a BRCA1 or BRCA2 Mutation. NEJM 2001; 345: 159-164
    CrossrefPubMedGoogle Scholar
  • 11 Yao K. Sisco M. Bedrosian I. Contralateral prophylactic mastectomy: current perspectives. Int J Womens Health 2016; 18: 213
    PubMedGoogle Scholar
  • 12 Meindl A. Ditsch N. Kast K. et al. Hereditary breast and ovarian cancer: new genes, new treatments, new concepts. Dtsch Arztebl Int 2011; 108: 323-330
    PubMedGoogle Scholar
  • 13 Heemskerk-Gerritsen BAM. et al. Improved overall survival after contralateral risk-reducing mastectomy in brca1/2 mutation carriers with a history of unilateral breast cancer: A prospective analysis. Int J Cancer 2015; 136: 668-677
    PubMedGoogle Scholar